EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer

Taro Shibuki, Celine Hoyek, Ryne Ramaker, Madhuri Gottam, Makoto Ueno, Yasuyuki Kawamoto, Shinji Itoh, Kanae Inoue, Tadayoshi Hashimoto, Takao Fujisawa, Mitsuho Imai, Yoshiaki Nakamura und 13 weitere

Journal of Gastroenterology · 2026

DOI: 10.1007/s00535-026-02439-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, 2026. Verfasst von Taro Shibuki und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Suppor…. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Immune Checkpoint Inhibitors, Tumor Suppressor Protein p53. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

TP53 mutations are among the most frequent alterations in biliary tract cancer (BTC), but their prognostic relevance and predictive value for immune checkpoint inhibitors (ICI) remain unclear. We assessed clinico-molecular features, prognosis, and ICI efficacy by TP53 status in advanced BTC.

Methods

Patients with advanced BTC from Japan and the United States who underwent tissue- or plasma-based next-generation sequencing were retrospectively analyzed. Tissue-based sequencing was used for the primary analysis, and plasma ctDNA sequencing was evaluated as an exploratory cohort. Outcomes were compared between TP53 wild-type (WT) and TP53 -mutated groups. Treatment– TP53 interactions for non-ICI versus ICI-containing regimens were assessed using multivariable Cox models. Whole-transcriptome sequencing data were analyzed using TIDE and Hallmark gene set enrichment analysis.

Results

Among 336 patients in the tissue-based cohort, 177 (52.7%) had TP53 -mutated tumors. SMAD4, ERBB2, PTEN and CCNE1 co-alterations were enriched in TP53 -mutated tumors, whereas IDH1, BAP1 , and FGFR2 fusions were more frequent in WT tumors. TP53 mutations were independently associated with shorter PFS, whereas OS showed a similar but nonsignificant trend (PFS: HR 1.32, P = 0.04; OS: HR 1.32, P = 0.09). TP53 mutations were associated with shorter PFS in the non-ICI cohort but numerically longer PFS in the ICI cohort, with a significant treatment– TP53 interaction for PFS ( P < 0.01). Similar trends were observed in the plasma cohort. Transcriptomic analyses ( n = 59; all MSS) showed lower TIDE scores in TP53 -mutated tumors.

Conclusion

TP53 mutations were associated with poor prognosis and may predict greater benefit from ICI, supporting biomarker-driven stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsImmune Checkpoint InhibitorsTumor Suppressor Protein p53HumansFemaleMutationMaleRetrospective StudiesPrognosisAgedMiddle AgedTreatment OutcomeBiomarkers, TumorHigh-Throughput Nucleotide SequencingJapanAged, 80 and over

Stichwörter der Autor:innen

TP53Advanced biliary tract cancerImmune checkpoint inhibitorPrognosisSystemic therapy

Substanzen

Immune Checkpoint InhibitorsTumor Suppressor Protein p53TP53 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Ka…
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. tshibuki@east.ncc.go.jp.
  • Department of Hematology and Oncology, Mayo Clinic, Arizona, AZ, USA.
  • Duke Cancer Institute, Durham, NC, USA.
  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
  • Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.

Förderung

  • NCI NIH HHS
  • NIMHD NIH HHS

Zitieren

APA

Shibuki, T., Hoyek, C., Ramaker, R., Gottam, M., Ueno, M., Kawamoto, Y., Itoh, S., Inoue, K., Hashimoto, T., Fujisawa, T., Imai, M., Nakamura, Y., Bando, H., Pirozzi, A., Zheng-Lin, B., Abidoye, O., Eslinger, C. R., Sonbol, M. B., Babiker, H., …, & Ikeda, M. (2026). Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer. Journal of Gastroenterology. https://doi.org/10.1007/s00535-026-02439-9

Vancouver

Shibuki T, Hoyek C, Ramaker R, Gottam M, Ueno M, Kawamoto Y, et al. Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer. Journal of Gastroenterology. 2026. doi:10.1007/s00535-026-02439-9

BibTeX
@article{Shibuki2026,
  author = {Shibuki, Taro and Hoyek, Celine and Ramaker, Ryne and Gottam, Madhuri and Ueno, Makoto and Kawamoto, Yasuyuki and Itoh, Shinji and Inoue, Kanae and Hashimoto, Tadayoshi and Fujisawa, Takao and Imai, Mitsuho and Nakamura, Yoshiaki and Bando, Hideaki and Pirozzi, Angelo and Zheng-Lin, Binbin and Abidoye, Oluseyi and Eslinger, Cody R and Sonbol, Mohamad Bassam and Babiker, Hani and Tran, Nguyen and Morizane, Chigusa and Strickler, John H and Yoshino, Takayuki and Bekaii-Saab, Tanios and Ikeda, Masafumi},
  title = {Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer},
  journal = {Journal of Gastroenterology},
  year = {2026},
  doi = {10.1007/s00535-026-02439-9}
}
Kostenlos starten →